All In MedTech

Device Trial Radar · NCT07620548

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

A Randomized Phase II Study of the Efficacy of Laser Interstitial Thermal Therapy (LiTT) Combined With Cemiplimab Versus Physician's Choice Chemotherapy in Recurrent Glioblastomas

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

May 31, 2031

Study completion Nov 30, 2032

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals
First posted
Jun 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).

Conditions

  • Glioblastoma
  • Glioblastoma, IDH-wildtype
  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Interventions

  • NeuroBlate® Laser Ablation Laser Interstitial Thermal TherapyDevice

    LiTT, or magnetic resource imaging (MRI)-guided laser ablation, is a minimally invasive surgery approved for cytoreductive treatment of brain tumors. It employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MRI imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.

  • CemiplimabDrug

    Cemiplimab is a programmed death receptor-1 (PD-1)-blocking antibody that is administered intravenously at 350mg over 30 minutes every 3 weeks on an outpatient basis.

  • ChemotherapyDrug

    Adjuvant chemotherapy will be decided by the physician's choice of best fit by patient, including the agent(s), dosing, and schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) at Month 6 (PFS6)Time frame: Start of treatment through 6 months after start of treatment (month 6)
  2. Overall survival (OS) at Month 18 (OS18)Time frame: Start of treatment through 18 months after start of treatment (month 18)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.